Enstilar Generic Name & Formulations
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%; foam.
Vit. D3 derivative + topical steroid.
Enstilar Dosage and Administration
Adults and Children
<12yrs: not established. ≥12yrs: apply to affected areas once daily for up to 4 weeks; max 60g every 4 days. Discontinue when control is achieved. Do not occlude.
Enstilar Boxed Warnings
Avoid use near eyes, on face, groin, or axillae, or if atrophy is present at treatment site. Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, or hyperglycemia occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Flammable. Allergic contact dermatitis. Pregnancy. Nursing mothers.
Systemic absorption potentiated by other corticosteroids.
Enstilar Adverse Reactions
Application site irritation and pruritus, folliculitis, skin hypopigmentation, hypercalcemia, urticaria, psoriasis exacerbation.
Enstilar Clinical Trials
Enstilar Patient Counseling